there are still many doubts as to its ability to replace antibiotics. Major concerns over the 52 use of phage therapy include neutralization of phages by the spleen/liver and by the 53 immune system, their narrow host range, bacterial resistance to the phage, and lack of 54 sufficient pharmacokinetic and efficacy studies in humans and animals (1, 11).
55
A recent study used phages as a genetic tool to increase bacterial susceptibility to It also demonstrated that phage-mediated gene transfer combined with antibiotics 61 increases the survival of mice infected with pathogenic E. coli. Overall, the study showed 62 that transferring genes by phage M13 weakens the bacteria, and render them more 63 susceptible to killing by antibiotics. We believed that some aspects of that study required 64 further modification. First, the transferred genes target a beneficial pathway in bacteria, 65 and therefore significantly reduce the fitness of the bacteria harboring this phage.
66
Consequently, negative selection pressure is constantly being applied against transfer of 67 these genes by the M13 phages. Second, no mechanism to facilitate genetic transfer of the 68 M13 genes was used: high multiplicity of infection in the experimental settings 69 compensated for this shortcoming. Nevertheless, such settings cannot be used in field 70 experiments. Third, the phage was experimentally tested in vivo, in mice, but immune 71 responses against it were not examined. Therefore, despite the novelty of that study in 72 terms of unique genetic-targeting by phages, the end result is very similar to conventional 73 phage-therapy practices, in which phages are used to directly kill the pathogen.
74
Different approaches make use of phages as "disinfectants" of pathogens present 75 on edible foods, plants, and farm animals. In addition to increasing the shelf life of these 76 products, the treatment is intended to prevent occasional outbreaks of disease. The US
77
Food and Drug Administration recently approved the use of an anti-Listeria phage 78 cocktail for application on meat and poultry as a preventive measure against Listeria (5).
79
Other phage cocktails have been approved as food additives in Europe, and many are 
83
Here we present a proof-of-principle for genetic delivery of constructs using 84 phages to target pathogens in the environment. In the described system, phages are 85 genetically engineered to reverse the pathogens' drug resistance, thereby restoring their 86 sensitivity to antibiotics. The phages transfer, by lysogenization into the pathogens, a 87 drug-sensitizing DNA cassette, which was previously shown to render bacteria sensitive 88 to agents to which they had acquired resistance (6). Pathogens that are lysogenized by the 89 designed phages are selected by tellurite because the phage is engineered to contain a 
MATERIALS AND METHODS

98
Bacterial strains. Bacterial strains used in this study are listed in Table S1 in the   99 supplemental material, as well as in Tables 1 and 2.   100 Oligonucleotides. Oligonucleotides used in this study are listed in Table S2 from the E. coli chromosome using primers N1/N2 (Table S2) for λ-RpsLΔ4-tell, λ-
130
RpsL-wt-tell, λ-RpsL-sil-tell, λ-Ctrl-tell, and λ-GyrA-tell (Fig. 1B) . Primers RE22/N2 131 (Table S2) were used for construction of λ-2xRpsL-tell. The obtained PCR products were 132 used for homologous recombination-based genetic engineering as described below.
133
Sequences of the phage inserts are presented in the supplemental material.
134
Homologous recombination-based genetic engineering. the bacteria were recovered in 1 ml LB for 1 h in a 32°C shaking water bath and 148 inoculated on selection plates containing 1 to 4 μg/ml tellurite. The DNA insertion into 149 the resulting phages, λ-RpsLΔ4-tell, λ-RpsL-wt-tell, λ-RpsL-sil-tell, λ-Ctrl-tell, λ-GyrA-150 tell, and λ-2xRpsL-tell, was confirmed by PCR using primer 233F along with 232F or 151 232R. were inoculated on appropriate selection plates and incubated overnight at 32°C.
157
Lysogens emerged on selection plates to which the phage carried a resistance gene. shaking, 100 μl Na-citrate and 500 μl LB were added. Cultures were incubated at 37°C or 170 32°C for 45 or 60 min, respectively, then 3 ml of warm LB supplemented with 0.7% agar 171 was added and the suspension was poured onto a plate containing the appropriate drug. strains to streptomycin were then determined. As shown in Fig. 2A RpsL-wt-tell, λ-RpsL-sil-tell, and λ-RpsLΔ4-tell (see the supplemental material for maps 328 of the DNA inserts in the phages). One of the streptomycin-resistant strains used above, of the resistant mutants (Fig. 4A) . The MIC value for the λ-RpsLΔ4-tell lysogen was 200 334 μg/ml, compared to 25 μg/ml and 50 μg/ml for λ-RpsL-wt-tell and λ-RpsL-sil-tell,
335
respectively. Although significant, the sensitization was not as efficient as that observed 336 using plasmid delivery. tellurite-resistance genes, into λ phages, designated λ-GyrA-tell and λ-Ctrl-tell 373 respectively. We used these phages to lysogenize a nalidixic acid-resistant strain, Nal2,
374
harboring a S83L substitution in GyrA. The lysogens were selected on 4 μg/ml tellurite 375 and tested for sensitization by measuring MICs as described above, using nalidixic acid (Fig. S1) . Overall, these results indicate 383 that the proposed system can be used to target nalidixic acid resistance as well as 384 streptomycin resistance.
385
Proposed application, safety measures, and advantages of the system. The 
577
Phage λ encoding a single copy of wt gyrA (λ-GyrA-tell) sensitizes a nalidixic acid-578 resistant mutant, Nal2, compared to phage λ encoding a mock gene (λ-Ctrl-tell).
579
Triplicates of the different lysogens, at 10 4 CFU/spot, were spotted on plates with the 580 indicated streptomycin concentrations. Tellurite was supplemented at 4 μg/ml in all 581 plates. Plates were incubated overnight and photographed using MiniBis Pro (Bio-
582
Imaging Systems). A representative experiment out of three is presented. 
